TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion

Sponsor
The First Hospital of Hebei Medical University
Study ID
NCT07075562
Status
Completed

Conditions

  • Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab Arterial Perfusion plus TACE — DRUG
    The intervention consists of a combination treatment. Patients undergo transcatheter hepatic artery chemoembolization (TACE), a procedure involving localized delivery of chemotherapy and embolization of the tumor-feeding arteries. This is combined with a targeted arterial perfusion of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF).
  • Conventional Therapy — PROCEDURE
    Patients in the control group received conventional therapy, which typically consists of TACE alone for this patient population. This involves the selective catheterization of hepatic arteries supplying the tumor, followed by the infusion of chemotherapeutic agents and an embolic agent to induce tumor necrosis.

Study Details

This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with hepatocellular carcinoma (HCC) invading the portal vein. The study aims to evaluate the effects on tumor load, angiogenesis, and survival outcomes.

Key Dates

First listed
Jul 20, 2025
Start date
Jun 1, 2021
Status verified
Jul 2025
Primary completion
Mar 31, 2024
Completion
May 30, 2025

Study Design

Enrollment
180 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Observation Group (TACE + Bevacizumab)
    Patients randomized to this arm received transcatheter hepatic artery chemoembolization (TACE) combined with arterial infusion of bevacizumab.
  • Active Comparator: Active Comparator: Control Group (Conventional Therapy)
    Patients randomized to this arm received conventional therapy for HCC with portal vein invasion, serving as the active control.

Primary Outcome Measure

Change in Tumor Load [ Time Frame: Baseline (before treatment) and 3 months post-treatmen ]

Related Studies